Safety experience with caspofungin in pediatric patients.
We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, 1 week to 17 years of age. Caspofungin was administered for 1 to 87 (mean 12.1) days. The most common drug-related adverse events were fever, increased AST, increased ALT, and rash; few events were serious or required treatment discontinuation. Caspofungin was well tolerated in this pediatric population.
Zaoutis
Theoklis
T
Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. zaoutis@email.chop.edu
Lehrnbecher
Thomas
T
Groll
Andreas H
AH
Steinbach
William J
WJ
Jafri
Hasan S
HS
Maertens
Johan
J
Ngai
Angela L
AL
Chow
Joseph W
JW
Taylor
Arlene F
AF
Strohmaier
Kim M
KM
Bourque
Michael
M
Bradshaw
Susan K
SK
Petrecz
Maria
M
Kartsonis
Nicholas A
NA
D000293:Adolescent; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077336:Caspofungin; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D054714:Echinocandins / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D055666:Lipopeptides; D009181:Mycoses / Q000188:drug therapy*; D011446:Prospective Studies
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077336:Caspofungin